← Back to All US Stocks

Medirom Healthcare Technologies Inc. (MRM) Stock Fundamental Analysis & AI Rating 2026

MRM Nasdaq Services-Personal Services M0 CIK: 0001819704
Updated This Month • Analysis: Apr 2, 2026 • SEC Data: 2026-04-02
Combined AI Rating
SELL
58% Confidence
AGREEMENT
SELL
95% Conf
HOLD
22% Conf

📊 MRM Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: SELL with 95% confidence
Medirom Healthcare Technologies Inc. (MRM) receives a SELL rating with 58% confidence from our AI fundamental analysis based on SEC 10-K filings. Below is our complete MRM stock analysis for 2026.

Is Medirom Healthcare Technologies Inc. (MRM) a Good Investment?

Claude

Medirom Healthcare Technologies presents an uninvestable opportunity due to complete absence of reportable financial data, indicating either pre-revenue status, failed operations, or severe reporting deficiencies. Without any disclosed revenues, assets, liabilities, or operational metrics, fundamental analysis is impossible and investment risk is unquantifiable.

ChatGPT

Fundamental visibility is limited due to a lack of recent SEC financials. The business could benefit from steady wellness-service demand and operating leverage if utilization and same-store sales improve. Until audited results show sustained profitability, positive operating cash flow, and adequate liquidity, a cautious stance is warranted.

Why Buy Medirom Healthcare Technologies Inc. Stock? MRM Key Strengths

Claude
  • -No strengths identified
ChatGPT
  • + Exposure to recurring wellness/personal services demand
  • + Potential operating leverage from improved utilization and mix
  • + Ability to scale via franchising with lower capex needs

MRM Stock Risks: Medirom Healthcare Technologies Inc. Investment Risks

Claude
  • ! No revenue data available - company may be pre-revenue or non-operational
  • ! Complete absence of balance sheet metrics - cannot assess solvency or financial position
  • ! No cash flow reporting - unable to evaluate operational sustainability or liquidity
  • ! Only 1 metric available in entire dataset - severe data transparency or reporting failure
  • ! No insider purchases in 90 days - management may lack confidence in company prospects
  • ! Unknown data freshness - financial position and operational status are indeterminate
ChatGPT
  • ! Data gaps and limited reporting drive high uncertainty
  • ! Thin, labor- and rent-intensive margins vulnerable to cost inflation
  • ! Liquidity and leverage risk if operating cash flow stays weak

Key Metrics to Watch

Claude
  • * Revenue recognition and growth trajectory once disclosed
  • * Path to profitability and operating cash flow generation
  • * Balance sheet strength including cash reserves and debt levels
ChatGPT
  • * Operating cash flow and cash balance
  • * Same-store sales growth

Medirom Healthcare Technologies Inc. (MRM) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

MRM Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

MRM vs Services Sector: How Medirom Healthcare Technologies Inc. Compares

How Medirom Healthcare Technologies Inc. compares to Services sector averages

Net Margin
MRM 0.0%
vs
Sector Avg 10.0%
MRM Sector
ROE
MRM 0.0%
vs
Sector Avg 16.0%
MRM Sector
Current Ratio
MRM 0.0x
vs
Sector Avg 1.5x
MRM Sector
Debt/Equity
MRM 0.0x
vs
Sector Avg 0.7x
MRM Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Medirom Healthcare Technologies Inc. Stock Overvalued? MRM Valuation Analysis 2026

Based on fundamental analysis, Medirom Healthcare Technologies Inc. has mixed fundamental signals relative to the Services sector in 2026.

Return on Equity
N/A
Sector avg: 16%
Net Profit Margin
N/A
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Medirom Healthcare Technologies Inc. Balance Sheet: MRM Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

MRM Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

MRM SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Medirom Healthcare Technologies Inc. (CIK: 0001819704)

📋 Recent SEC Filings

Date Form Document Action
Dec 10, 2024 SC 13G tm2429027d1_sc13g.htm View →
Jan 25, 2023 SC 13D tm234310d1_sc13d.htm View →
Jan 6, 2023 SC 13D ea171283-sc13dkufu_medirom.htm View →
Jan 15, 2021 SC 13G a21-3204_1sc13g.htm View →

Frequently Asked Questions about MRM

What is the AI rating for MRM?

Medirom Healthcare Technologies Inc. (MRM) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 58% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are MRM's key strengths?

Claude: . ChatGPT: Exposure to recurring wellness/personal services demand. Potential operating leverage from improved utilization and mix.

What are the risks of investing in MRM?

Claude: No revenue data available - company may be pre-revenue or non-operational. Complete absence of balance sheet metrics - cannot assess solvency or financial position. ChatGPT: Data gaps and limited reporting drive high uncertainty. Thin, labor- and rent-intensive margins vulnerable to cost inflation.

What is MRM's revenue and growth?

Medirom Healthcare Technologies Inc. reported revenue of N/A.

Does MRM pay dividends?

Medirom Healthcare Technologies Inc. does not currently pay dividends.

Where can I find MRM SEC filings?

Official SEC filings for Medirom Healthcare Technologies Inc. (CIK: 0001819704) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is MRM's EPS?

Medirom Healthcare Technologies Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is MRM a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Medirom Healthcare Technologies Inc. has a SELL rating with 58% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is MRM stock overvalued or undervalued?

Valuation metrics for MRM: ROE of N/A (sector avg: 16%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

Should I buy MRM stock in 2026?

Our dual AI analysis gives Medirom Healthcare Technologies Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is MRM's free cash flow?

Medirom Healthcare Technologies Inc.'s operating cash flow is N/A, with capital expenditures of N/A.

How does MRM compare to other Services stocks?

Vs Services sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 16%), current ratio N/A (avg: 1.5).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 2, 2026 | Data as of: 2026-04-02 | Powered by Claude AI